

**AMENDMENTS TO THE CLAIMS**

The following is a complete, marked-up listing of revised claims with a status identifier in parenthesis, underlined text indicating insertions, and strike through and/or double-bracketed text indicating deletions.

**LISTING OF CLAIMS**

1. (Currently Amended) A substance carrier comprising hollow nanoparticles of a particle-forming protein, the hollow nanoparticles displaying an antibody against a specific cell or specific tissue, and encapsulating a substance to be transferred into a cell ~~for treating a disease,~~

the antibody being ~~a cancer specific antibody or anti-virus protein~~  
antibody displayed on the surface of the nanoparticles by binding to a ZZ tag fused with  
the particle-forming protein. and the particle-forming protein including a modified hepatitis B virus surface antigen ~~L proteins~~surface antigen large (L) protein.

2. – 4. (Cancelled).

5. (Previously Presented) The substance carrier as set forth in claim 1, wherein the antibody is a single chain antibody fused with the particle-forming protein.

6. (Previously Presented) The substance carrier as set forth in claim 1, wherein the hollow nanoparticles of a particle-forming protein are expressed in a eukaryotic cell.

7. (Previously Presented) The substance carrier as set forth in claim 6, wherein the eukaryotic cell is selected from a group consisting of a yeast cell, insect cell, and animal cell.

8. (Cancelled).

9. (Currently Amended) The substance carrier as set forth in claim 1, wherein the modified hepatitis B virus surface-antigen large(L) protein is modified to lack some of amino acids in a pre-S region.

10-13. (Cancelled).

14. (Currently Amended) The substance carrier as set forth in claim 1, wherein the ~~disease-treating~~ substance comprises a gene.

15. (Previously Presented) The substance carrier as set forth in claim 14, wherein the gene comprises a thymidine kinase (HSV1tk) gene derived from simple herpes virus.

16-28. (Cancelled).

29. (New) A nanoparticle comprising hollow nanoparticles of a particle-forming protein,  
the particle-forming protein being fused with a ZZ tag, and  
the particle-forming protein including a modified hepatitis B virus surface antigen large(L) protein.